secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nascent Pharma Holdings, Inc. (—)
CIK:        0002042814
Form:       8-K12G3
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001493152-24-042727
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 3.03, 5.03, 5.02, 5.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nascent Pharma Holdings succeeds Can B Corp. as public holding company via stock-for-stock merger
--------------------------------------------------------------------------------

- Each share of Can B common and preferred converted 1:1 into equivalent Nascent share; no stockholder vote required.
- Outstanding shares: 71,239,311 common, 5 Series A, 1,100 Series C, 4,000 Series D preferred; all classes unchanged.
- Same board and officers continue: Marco Alfonsi (CEO), Stanley L. Teeple (CFO, Secretary).
- Nascent adopted a Code of Business Conduct and Ethics and an Incentive Stock Option Plan.
- New trading symbol not yet assigned; FINRA processing pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2042814/000149315224042727/0001493152-24-042727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2042814/000149315224042727/form8-k12g3.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer